Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 27Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 15Lymphoma 9Hodgkin Disease 9Neoplasms, Plasma Cell 5Myelodysplastic Syndromes 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 2Pancreatic Neoplasms 2Gliosarcoma 2Glioma 2Glioblastoma 2Warts 1Pinealoma 1Paraproteinemias 1Ovarian Neoplasms 1Neutropenia 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Medulloblastoma 1Lymphoproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hematologic Neoplasms 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × plerixafor × Clear all
NCT01288573 2017-05-16

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Sanofi

Phase 1/2 Completed
46 enrolled
CNS

Brain Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡